Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
5 evidence topics · 7 sources
Protein kinase C signaling downstream of mutant GNAQ and GNA11
“A key downstream player of the constitutively active G-protein alpha subunits (GNAQ or GNA11) is the phospholipase C/protein kinase C (PKC) signalling pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PKC signalling is a key node in the maintenance of cellular homoeostasis; in UM cells, it results in phosphorylation and increased transcript expression of RasGrp3, a guanine nucleotide exchange factor that transduces signalling from GNAQ/GNA11 to the MAPK signalling pathway through PKC delta” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Darovasertib: oral, selective inhibitor of classical and novel PKC isoforms
Second-generation PKC inhibitor with activity restricted to GNAQ- or GNA11-mutant uveal melanoma cell lines
“LXS196 is a potent, second-generation, oral PKC inhibitor designed with improved pharmaceutical properties compared with AEB071.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LXS196 has a highly selective kinase profile affording increased tolerability in preclinical studies, with cellular activity restricted to UM cell lines containing mutant GNAQ or GNA11 and no activity observed in skin-derived melanoma cell lines driven by mutant B-Raf or N-Ras” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote